Literature DB >> 24603367

Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease.

Shigetaka Yoshida1, Kenichi Ishizawa, Nobuhiro Ayuzawa, Kohei Ueda, Maki Takeuchi, Wakako Kawarazaki, Toshiro Fujita, Miki Nagase.   

Abstract

BACKGROUND/AIMS: Obesity and diabetes are intimately interrelated, and are independent risk factors for kidney disease. Overactivation of mineralocorticoid receptor (MR) is implicated in end organ damage of both pathologies. But the underlying mechanism of MR activation in kidney remains uncertain. We explored the involvement of Rac1, which we previously identified as a ligand-independent MR activator, in renal MR activation in vitro and in vivo.
METHODS: We evaluated the MR activity and Rac1 activity under high-glucose stimulation using luciferase reporter system and glutathione S-transferase pull-down assay in cultured mesangial cells. To elucidate the role of Rac1 in vivo, we employed KKA(y), a mouse model of obesity-related type 2 diabetes, which spontaneously developed massive albuminuria and distinct glomerular lesions accompanied by increased plasma aldosterone concentration.
RESULTS: High-glucose stimulation increased Rac1 activity and MR transcriptional activity in cultured mesangial cells. Overexpression of constitutively active Rac1 activated MR, and glucose-induced MR activation was suppressed by overexpression of dominant negative Rac1 or Rac inhibitor EHT1864. In KKA(y), renal Rac1 was activated, and nuclear MR was increased. EHT1864 treatment suppressed renal Rac1 and MR activity and mitigated renal pathology of KKA(y) without changing plasma aldosterone concentration.
CONCLUSION: Our results suggest that MR activation plays an important role in the nephropathy of KKA(y) mice, and that glucose-induced Rac1 activation, in addition to hyperaldosteronemia, contributes to their renal MR activation. Along with MR blockade, Rac inhibition may potentially be a preferred option in the treatment of nephropathy in obesity-related diabetic patients. 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24603367     DOI: 10.1159/000358758

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  15 in total

1.  EHT 1864, a small molecule inhibitor of Ras-related C3 botulinum toxin substrate 1 (Rac1), attenuates glucose-stimulated insulin secretion in pancreatic β-cells.

Authors:  Vaibhav Sidarala; Rajakrishnan Veluthakal; Khadija Syeda; Anjaneyulu Kowluru
Journal:  Cell Signal       Date:  2015-02-26       Impact factor: 4.315

Review 2.  Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

3.  Inhibition of prostate smooth muscle contraction and prostate stromal cell growth by the inhibitors of Rac, NSC23766 and EHT1864.

Authors:  Y Wang; T Kunit; A Ciotkowska; B Rutz; A Schreiber; F Strittmatter; R Waidelich; C Liu; C G Stief; C Gratzke; M Hennenberg
Journal:  Br J Pharmacol       Date:  2015-05-05       Impact factor: 8.739

Review 4.  The kidney in obesity.

Authors:  Josep Redon; Empar Lurbe
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

5.  High Elmo1 expression aggravates and low Elmo1 expression prevents diabetic nephropathy.

Authors:  Catherine K Hathaway; Albert S Chang; Ruriko Grant; Hyung-Suk Kim; Victoria J Madden; C Robert Bagnell; J Charles Jennette; Oliver Smithies; Masao Kakoki
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

Review 6.  Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Authors:  Jonatan Barrera-Chimal; Ixchel Lima-Posada; George L Bakris; Frederic Jaisser
Journal:  Nat Rev Nephrol       Date:  2021-10-21       Impact factor: 28.314

Review 7.  Kidney and epigenetic mechanisms of salt-sensitive hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2021-02-24       Impact factor: 28.314

Review 8.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 9.  Vascular Mineralocorticoid Receptor: Evolutionary Mediator of Wound Healing Turned Harmful by Our Modern Lifestyle.

Authors:  Lauren A Biwer; Mary C Wallingford; Iris Z Jaffe
Journal:  Am J Hypertens       Date:  2019-01-15       Impact factor: 2.689

Review 10.  The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury.

Authors:  Nobuhiro Ayuzawa; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2021-01-04       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.